What is Aurobindo Pharma Ltd's PE ratio?

Aurobindo Pharma Ltd trades at a P/E ratio of 25.10.

What is Aurobindo Pharma Ltd's market cap?

Aurobindo Pharma Ltd's market capitalisation is ₹88,979 Cr.

When did Aurobindo Pharma Ltd last report results?

Aurobindo Pharma Ltd last reported Q4FY26 results on 21 May '26.

What is Aurobindo Pharma Ltd's ROE?

Aurobindo Pharma Ltd's return on equity (ROE) is 10.1%.

What sector is Aurobindo Pharma Ltd in?

Aurobindo Pharma Ltd (AUROPHARMA) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Aurobindo Pharma Ltd (AUROPHARMA)

₹1,532.00

Mkt cap

₹88,979 Cr

P/E ratio

25.10

P/B

2.35

Div yield

0.26%

ROE

10.10%

ROCE

12.80%

EPS (TTM)

₹61.04

Book value

₹652

52W range

1,022–1,621

Sector

Healthcare

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

NSE AUROPHARMABSE 524804www.aurobindo.com

Health check

Constructive

ValuationCheap

ProfitabilityAverage

GrowthModerate

TechnicalsBullish

52-week range

−5.46% from high

₹1,532

₹1,022+49.87% from low₹1,621

Current

₹1,532.00

Prev close

₹1,527.10

Day

+0.32%

Price performance

+0.32%

−1.77%

−1.49%

+8.36%

+34.19%

+32.73%

YTD

+26.05%

Financials

F

Revenue, profit & margin

P/E ratio

25.1×

AUROPHARMA is 26% below the sector median of 34.0×

AUROPHARMA25.1×

Sector median34.0×

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	6,473	6,851	7,219	7,352	7,580	7,567	7,796	7,979	8,382	7,868	8,286	8,646	8,853
Expenses	5,477	5,702	5,846	5,753	5,920	5,949	6,230	6,401	6,622	6,265	6,608	6,873	7,103
Operating Profit	996	1,149	1,373	1,599	1,660	1,618	1,566	1,578	1,760	1,603	1,678	1,773	1,750
OPM %	15%	17%	19%	22%	22%	21%	20%	20%	21%	20%	20%	21%	20%
Other Income	135	47	188	163	14	221	136	159	135	107	122	123	117
Interest	56	57	68	76	89	111	113	118	115	98	95	93	98
Depreciation	346	327	418	423	354	404	382	419	444	406	429	465	479
Profit before tax	730	812	1,076	1,262	1,230	1,324	1,207	1,200	1,335	1,207	1,276	1,339	1,291
Tax %	31%	30%	30%	26%	26%	31%	32%	30%	32%	32%	34%	32%	29%
Net Profit	506	570	752	940	907	918	817	846	903	824	848	910	921
EPS in Rs	8.64	9.74	12.92	15.98	15.51	15.69	14.07	14.56	15.56	14.20	14.61	15.67	15.86
Raw PDF

Earnings

EResults dates & reactions

No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.11% · closed higher next day 29 of last 60

	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Broadcast	12 Aug '23◦	10 Nov '23	10 Feb '24◦	25 May '24◦	10 Aug '24◦	9 Nov '24◦	6 Feb '25◦	27 May '25	4 Aug '25◦	5 Nov '25◦	9 Feb '26◦	21 May '26◦
Earnings day	+0.98%	+3.04%	+1.55%	−3.13%	+0.83%	−2.90%	−0.01%	+0.87%	−1.02%	−0.74%	−6.61%	−5.38%
+1 day	+1.23%	+3.03%	+2.32%	−1.14%	+3.87%	−4.53%	−1.23%	−2.80%	−1.66%	−2.20%	−4.74%	−5.95%
+5 days	−2.38%	+4.98%	+3.76%	−0.62%	+6.04%	−5.83%	−5.07%	−3.14%	−2.95%	+5.32%	−1.41%	−7.31%
+15 days	−1.34%	+7.91%	+8.75%	+0.62%	+6.88%	−5.13%	−10.85%	−6.03%	−5.88%	+7.55%	−0.69%	−8.95%
+30 days	+1.98%	+12.50%	+6.70%	+7.88%	+3.55%	−5.37%	+0.26%	−2.81%	+3.53%	+5.24%	+8.65%	+2.35%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	XBRL	XBRL	XBRL

Corporate actions

CLast 6 months

Kind	Value	Ex-date	Record
other Buy Back	—	17 Apr '26	17 Apr '26

Shareholding

Sas of Jun 2026

51.88%Promoter

Promoters51.88%0.06

FIIs16.38%1.14

DIIs25.05%0.77

Public6.63%0.45

Government0.05%

Ownership trend

Peers

P8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,941.10	37.48	4,65,723	0.82%	2,710	+13.58%	14,612	+12.76%	20.53%
Divi's Lab.	₹7,248.50	73.36	1,92,425	0.41%	751	+13.44%	2,831	+9.52%	21.97%
Torrent Pharma.	₹4,961.50	86.10	1,88,697	0.77%	364	−20.58%	4,197	+41.84%	15.19%
Cipla	₹1,410.60	31.84	1,13,955	0.92%	786	−39.19%	7,119	+2.33%	15.49%
Zydus Lifesci.	₹1,108.70	20.38	1,10,593	0.09%	1,341	+21.92%	7,587	+16.22%	21.14%
Lupin	₹2,370.50	19.06	1,08,387	0.76%	1,469	+101.49%	7,475	+31.89%	29.93%
Mankind Pharma	₹2,507.20	51.44	1,03,559	0.04%	559	+34.23%	3,443	+11.81%	13.53%
Aurobindo Pharma	₹1,532.00	25.08	88,979	0.26%	921	+1.97%	8,853	+5.62%	12.80%
Median: 157 Co.	₹432.05	34.03	1,978	0.10%	15	+28.10%	176	+17.66%	15.10%

Filings

D

Annual reports15

Financial Year 2025bse Financial Year 2024bse Financial Year 2023bse Financial Year 2022bse Financial Year 2021bse Financial Year 2020bse Financial Year 2019bse Financial Year 2018bse Financial Year 2017bse Financial Year 2016bse Financial Year 2015bse Financial Year 2014bse Financial Year 2013bse Financial Year 2013nse Financial Year 2012bse

Credit ratings6

Rating update 10 Junfitch Rating update 11 Mar 2025fitch Rating update 20 Dec 2023fitch Rating update 20 Oct 2022fitch Rating update 6 Aug 2021fitch Rating update 4 Aug 2021fitch

Announcements5

Announcement under Regulation 30 (LODR)-Press Release / Media Release 35m - Is being issued in connection with signing non exclusive voluntary license agreement with MSD.Announcement under Regulation 30 (LODR)-Acquisition 1d - Apitoria to acquire 80% of A1 Biochem Group for USD 17 million; completion expected in 90-120 days.ANVISA Approval For Curateq Biologics'' Biosimilars Manufacturing Facility 21 Jul - CuraTeQ Biologics received ANVISA approval for Hyderabad biosimilars facility on July 21, 2026.Announcement under Regulation 30 (LODR)-Acquisition 10 Jul - PT Auro Pharm Indonesia incorporated in Indonesia on July 1, 2026; 100% subsidiary for manufacturing operations.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2 Jul - Regulation 74(5) certificate filed for quarter ended June 30, 2026.